DHR - Danaher Corporation
A scientific instrument and diagnostics conglomerate whose portfolio of precision tools is essential to pharmaceutical manufacturing, life sciences, and environmental testing.
Finlify Score
28.6 / 100
Data Quality
FULL
Penalty
0.0
Sector
Health Care
Close Price
$181.10
+0.56%
52W Range
$160.93 - $242.80
Market Cap
$129.3B
+0.6%Compared to previous day
2026 Q1 Revenue
$6.0B
-13.0%Changes from last reporting quarter
2026 Q1 EPS
$1.00
Diluted shares
Analyst Rating
30 analysts in latest ratings feed
RSI
59.4
40-70 moderate
2Y Range Position
17%
-35.7% from high / +12.5% from low
Beta
0.80
Relative to market benchmark
MACD
0.62
MACD line 1.53 / signal line 0.92
Fundamental Trend
Growth 13.1Financial Health
Quality 78.5Data Quality
FULLValuation Reference
Price Chart
Close price, two-year source window
Finlify Score
AVOID28.6 / 100
Score History
Finlify Score and component trend
Financial Statements
Calendar year view. Figures are estimates only. For official figures, refer to the company website.
| 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | |
|---|---|---|---|---|
| Revenue | $6.0B-13.0% | $6.8B+13.0% | $6.1B+2.0% | $5.9B+3.4% |
| Gross Profit | $3.6B-9.5% | $4.0B+12.6% | $3.5B0.0% | $3.5B+0.3% |
| Operating Income | $1.3B-10.5% | $1.5B+30.2% | $1.2B+51.8% | $760M-40.3% |
| Net Income | $1.0B-14.0% | $1.2B+31.8% | $908M+63.6% | $555M-41.8% |
Columns use the calendar quarter of each reported period end date. QoQ is shown for adjacent company reporting quarters only.
AI Signal
Generated Jun 16, 2026
The Finlify signal for DHR is AVOID, with a Finlify Score of 28.1 out of 100. This low score appears to be driven by weak Relative Strength, Accumulation/Volume, and Fundamental Trend components, despite a relatively strong Financial Quality score.
Technical
The Relative Strength score of 13.5/100 and Accumulation/Volume score of 14.9/100 suggest a lack of significant buying pressure and underperformance relative to the broader market. While DHR has seen a positive 20-day return of 9.5%, its 60-day return indicates a decline of -6.0%, and the asset is currently -25.6% from its 52-week high, which may reflect recent downward momentum. The RSI(14) at 51.1 appears neutral.
Fundamentals
The Fundamental Trend score of 13.1/100 indicates potential concerns regarding the company's underlying business momentum. Despite this, the Financial Quality score is relatively strong at 78.5/100, suggesting a sound financial structure. Valuation metrics appear elevated, with a P/E ratio of 35.3x and a P/S ratio of 5.2x, which may suggest the stock is trading at a premium. DHR has a Beta of 0.8, indicating lower volatility compared to the market, and offers a modest dividend yield of 0.89%.
Macro Context
With inflation indicators like CPI YoY at 4.3% and Core PCE YoY at 3.3% remaining elevated, and a 10Y Treasury Yield at 4.5%, the current macro environment may present headwinds for growth-oriented assets. The positive but narrow yield spread of 0.4% could suggest a cautious economic outlook, potentially impacting investor sentiment towards stocks with high valuations.
Key Risks
- Weak Momentum & Accumulation: The very low Relative Strength (13.5/100) and Accumulation/Volume (14.9/100) scores suggest a lack of market interest and potential for continued underperformance.
- Challenging Fundamental Trend: A Fundamental Trend score of 13.1/100 indicates potential deterioration in underlying business performance or outlook, despite a strong Financial Quality.
- Elevated Valuation in High-Rate Environment: A P/E of 35.3x and P/S of 5.2x appear high, which may be particularly scrutinized in an environment with a 10Y Treasury Yield of 4.5%.